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RÉSUMÉ 
Altérations de l’épigénome dans le cancer du cerveau: perte de 5-
hydroxyméthylcytosine. 
 
Par 
Carolyne Mary Lowry 
Programmes de Sciences des radiations et imagerie biomédicale 
 
Mémoire présenté à la Faculté de médecine et des sciences de la santé en vue de l’obtention 
du diplôme de maitre ès sciences (M.Sc.) en Sciences des radiations et imagerie 
biomédicale, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, 
Sherbrooke, Québec, Canada, J1H 5N4 
 
5Mtéthylcytosine (5mC) est une marque épigénétique qui peut être oxydée en 5-
hydroxyméthylcytosine (5hmC) par ten-eleven translocation (TET) oxygénases. Ceci 
amène à l’étape initiale de la déméthylation de 5mC. Le niveau de 5hmC est plus élevé 
dans le cerveau par rapport aux autres organes. Par contre, ce niveau a une réduction 
marquante au cours du développement d’une tumeur cérébrale, notamment le glioblastome 
multiforme (GBM). Toutefois, il n’y a aucun mécanisme connu pour expliquer cette 
anomalie. Les objectifs de ce projet étaient de (1) discerner l’implication de la voie de 
déméthylation obtenu par médiation de TET et (2) d’avoir une compréhension plus 
profonde de la constitution épigénétique des tumeurs cérébraux. (1) Des cellules U87 ont 
été incubées avec 5mC, 5hmC, 5-fomylcytosine (5fC) et une co-incubation de 5hmC avec 
3,4,5,6-tétrahydro-2’-déoxyuridine (dTHU). Les échantillons ont été récoltés à 0, 24, 48, 96 
heures. (2) 130 tumeurs cérébraux (GBM = 79; grade II/III = 51) étaient obtenus 
directement de chirurgie et mise en suspension dans un tampon d’extraction d’ADN le jour 
même.  Les échantillons d’U87 et de tissu tumoral ont subi les protocoles d’extraction et de 
digestion d’ADN. Le pourcentage par cytosine (%/C) était calculé par la quantification de 
5mC, 5hmC, 5fC, 5-hydroxyméthyluracile (5hmU) et 5-formyluracile (5fU) en utilisant 
LC-MS/MS. (1) Les incubations d’U87 ont démontrées la possibilité augmenter les niveaux 
génomique de 5hmC, mais aussi une légère augmentation des niveaux de 5mC. Les niveaux 
de 5hmC ont accru de 1.9 fois après 96hrs. Par contre, aucune variation n’a été observée 
dans les niveaux de 5fC. Les incubations de 5hmC et 5fC ont été accompagnées par une 
élévation des niveaux de 5hmU et 5fU respectivement. L’addition de dTHU avec 5hmC 
avait diminué l’incorporation de 5hmU par 65%. (2) Dans les tumeurs cérébraux, les 
niveaux moyens de 5mC, 5hmC et 5fC étaient de 4.0, 0.15 et 0.021%/C respectivement. 
Les quantités de 5hmU et 5fU étaient grandement plus faible dans le GBMs que dans les 
tumeurs de bas grades. La présence de 5hmU et 5fU dans les tumeurs et leur augmentation 
durant l’incubation des U87 indiquent une activité de désamination, qui peut, en particulier, 
entraver les niveaux de 5hmC. En outre, malgré l’incubation avec 5mC, les niveaux de 
5hmC et 5fC n’ont pas augmentés suggérant un dysfonctionnement de TET. L’activité de 
TET est maintenue dans GBM, mais altérée dans les tumeurs de bas grades à cause de 
mutation isocitrate dehydrogenase-1 (IDH1). Par conséquent, la forte activité de 
désamination et la déficience en TET peuvent conduire à une réduction épigénétique. 
Mots clés: Lésions et réparation d’ADN, épigénétique, GBM, Cellules U87, LC-MS/MS
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SUMMARY 
 Alterations of the epigenome in brain cancer: loss of 5-hydroxymethylcytosine. 
 
By 
Carolyne Mary Lowry 
Science des radiations et imagerie biomédicale Program 
 
Thesis presented at the Faculty of medicine and health sciences for the obtention of 
Master’s degree diploma maitre ès sciences (M.Sc.) in Sciences des radiations et imagerie 
biomédicale, Faculty of medicine and health sciences, Université de Sherbrooke, 
Sherbrooke, Québec, Canada, J1H 5N4 
 
5-Methylcytosine is an epigenetic mark, which can be oxidized to 5-
hydroxymethylcytosine (5hmC) in DNA by ten-eleven translocation (TET) oxygenases. It 
is an initial step in the demethylation of 5mC. Levels of 5hmC is relatively high in the brain 
compared to other organs, but these levels are known to be significantly reduced during the 
development of a brain tumor, especially in glioblastoma multiforme (GBM). However, no 
known mechanisms may fully explain this abnormality. The objectives of my project were 
to (1) understand the implications of the demethylation pathway mediated by TET, and (2) 
gain a deeper insight in the epigenetic make-up of brain tumors. (1) U87 cells were 
incubated with 5mC, 5hmC, 5-formylcytosine (5fC) or co-incubated of 5hmC with 3,4,5,6-
tetrahydro-2’-deoxyuridine (dTHU) over a timeline of 0, 24, 48 and 96 hours. (2) 130 brain 
tumors (GBM= 79; grade II/III= 51) were obtained directly from surgery and immediately 
suspended in DNA extraction buffer. Both cell samples and tumor tissues underwent DNA 
extraction and DNA digestion protocols. The percent per cytosine (%/C) was obtained by 
quantification of 5mC, 5hmC, 5fC, 5-hydroxymethyluracil (5hmU) and 5formyluracil 
(5fU) using LC-MS/MS. (1) Cellular incubations showed that it is possible to increase 
levels of 5hmC in DNA, but also a slight increase in 5mC levels throughout the experiment. 
5HmC levels dramatically increased by 1.9-fold after 96h. On the other hand, no increase 
was observed in 5fC levels. Both 5hmC and 5fC incubations were accompanied by high 
increases in 5hmU and 5fU levels respectively. The addition of dTHU to the 5hmC 
incubation decreased 5hmU incorporation by 65%. (2) The average levels of 5mC, 5hmC 
and 5fC, in brain tumors, were 4.0, 0.15 and 0.021 %/C respectively. 5HmU and 5fU levels 
were present at comparable levels of 5hmC and 5fC. Levels of 5hmC, 5hmU and 5fU were 
significantly lower in the DNA of GBM specimens. There was a strong correlation between 
5mC with 5hmC and 5fC in GBM, but this was absent in low grade tumors. The presence 
of 5hmU and 5fU in brain tumor and the increase in their levels during cell incubations 
indicate a deamination activity in these cancerous cells, which may impinge on the cellular 
levels of 5hmC, in particular. Furthermore, upon the incubations with 5hmC, downstream 
levels of 5fC did not increase suggesting a TET malfunction. TET activity is maintained in 
GBMs, but impaired in low grade tumors due to isocitrate dehydrogenase-1 (IDH1) 
mutations. Therefore, in brain tumors, a strong deamination activity and TET impairment 
may lead to epigenetic reduction of 5hmC. 
Keywords: DNA damage, DNA repair, Epigenetics, GBM, U87 cells, LC-MS/MS  
iv 
 
iv 
 
TABLE OF CONTENT 
Résumé ............................................................................................................................................. ii 
Summary ....................................................................................................................................... iii 
Table of content ........................................................................................................................... iv 
List of figures ................................................................................................................................ vi 
List of tables ................................................................................................................................ vii 
List of abbreviation .................................................................................................................. viii 
Introduction ................................................................................................................................... 1 
Problematic ............................................................................................................................................ 11 
Objectives ........................................................................................................................................................... 11 
Hypotheses ........................................................................................................................................................ 11 
Article 1 ......................................................................................................................................... 13 
Abstract ................................................................................................................................................... 16 
Introduction ........................................................................................................................................... 17 
Methods and Materials ....................................................................................................................... 19 
Cell Culture and Treatment ......................................................................................................................... 19 
Toxicity ................................................................................................................................................................ 19 
DNA Extraction ................................................................................................................................................ 19 
DNA Digestion .................................................................................................................................................. 20 
LC-MS/MS analysis ......................................................................................................................................... 21 
Statistics .............................................................................................................................................................. 21 
Results ...................................................................................................................................................... 22 
Discussion ............................................................................................................................................... 28 
Acknowledgements ............................................................................................................................. 30 
References .............................................................................................................................................. 31 
Secondary Project (unpublished) ........................................................................................ 36 
Materials and Methods ....................................................................................................................... 36 
Tumor Specimens ........................................................................................................................................... 36 
Sample Preparation ........................................................................................................................................ 36 
Statistics .............................................................................................................................................................. 37 
Results ...................................................................................................................................................... 38 
  
v 
v 
Comparison of methyl cytosine related modifications in tumor specimens .......................... 38 
Correlations between modifications ....................................................................................................... 40 
Discussion .................................................................................................................................... 42 
DNA Hypo/Hypermentylation ......................................................................................................... 42 
5hmC in brain tumors ........................................................................................................................ 44 
Implications of TET ............................................................................................................................. 46 
Deamination activity .......................................................................................................................... 48 
Conclusion.................................................................................................................................... 51 
Acknowledgements .................................................................................................................. 52 
List of references ....................................................................................................................... 53 
vi 
 
vi 
 
LIST OF FIGURES 
Introduction 
Figure 1 Cytosine Methylation ............................................................................................... 4 
Figure 2 Conversion of 5mC to 5hmC...…………………………………………………….5 
Figure 3 TET Oxidative Process……………………………………….……………………6 
Figure 4 Base Excision Repair Mechanism ………………………..……………………….8 
 
Article 1 
Figure 1 Structure of DNA methylation and demethylation intermediates. ......................... 22 
Figure 2 Toxicity 5mC, 5hmC, 5fC, 5hmU and 5fU nucleosides toward U87 cells in 
culture....……………………………………….…………………………………...23 
Figure 3 Treatment of cells with 5mC ………………………..………………………...…24 
Figure 4 Treatment of cells with 5hmC ……………..……………..……………………...25 
Figure 5 Treatment of cells with 5fC ………………………..………………………….…26 
Figure 6 Treatment of cells with 5hmC in the presence of dTHU ………..…………….…27 
 
Secondary Project (Unpublished) 
Figure 5 LC-MS/MS analysis of 5methylcytosine oxidation products in DNA………..….37 
Figure 6 Levels of 5mC in brain tumors. .............................................................................. 38 
Figure 7 Levels of 5hmC and 5fC in brain tumors....……………………………………...39 
Figure 8 Levels of 5hmU and 5fU in brain tumors……………………………………...…40 
Figure 9 Correlation between 5mC with 5hmC and 5fC…………………………………..41 
Figure 10 DNA methylation with the aid of S-adenosylmethionine……..……...............…46 
Figure 11 Demethylation pathway promoted in GBMs...…………………………..……...47 
Figure 12 Epigenetic salvage and reincorporation process………………………………...50 
vii 
 
vii 
 
LIST OF TABLES 
 
Table 1 Correlation of 5mC and demethylation intermediates ............................................. 41 
viii 
 
viii 
 
LIST OF ABBREVIATION 
 
5caC 
5fC 
5fU 
5hmC 
5hmU 
5mC 
8-oxo-dG 
AID 
α-KG 
APOBEC 
BER 
°C 
C 
CDA 
CNS 
D 
DNMTs 
dTHU 
G 
GBM 
hMTH1 
IDH 
MGMT 
ROS 
SAH 
SAM 
T 
5-carboxylcytosine 
5-formylcytosine 
5-formyluracil 
5-hydroxymethylcytosine 
5-hydroxymethyluracil 
5-methylcytosine 
8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxo-dG) 
Activation-induced deaminase 
α-Ketoglutarate 
Apolipoprotein B mRNA-editing enzyme complex 
Base excision repair 
Celsius 
Cytosine 
Cytidine deaminase 
Central nervous system 
Deuterium 
DNA methyltransferases 
3,4,5,6-tetrahydro-2’-deoxyuridine 
Guanine 
Glioblastoma (Glioblastoma Multiforme) 
Human Mut T homologue 1 
Isocitrate dehydrogenase-1 
O6-methylguanine-DNA-methyltransferase 
Reactive oxygen species 
S-adenosylhomocysteine 
S-adenosylmethionine 
Thymine 
  
ix 
ix 
TET 
TDG 
WHO 
Ten-eleven translocation enzyme family 
Thymidine DNA glycosylase 
World Health Organisation 
1 
 
1 
 
INTRODUCTION 
 
Cancer is a known occurrence within the human population. It has drawn much 
attention in research, and has led to multiple efforts to both better understand it, as well as 
to find a solution to ease, if not cure, the suffering of those affected. Within the human 
population, cancer may be caused by various factors, such as endogenous factors, for 
example reactive by-products of our metabolism, as well as exogenous factors, for instance 
toxic chemicals and UV radiation (Irigaray et al. 2007).  
 Whatever the reason may be, cancer as a whole is considered to account for 40% of 
unnatural cause of death, thus ranking it as the number one cause. In 2015 alone, 196,900 
new cases of cancer where diagnosed in Canada (Canadian Cancer Society’s Advisory 
Committee on Cancer Statistics 2015). The varieties of cancers that may befall an 
individual are innumerable. There are some that have grabbed much attention throughout 
much of today’s media. Of these are breast, prostate, lung and colorectal cancers, which, 
despite the multiple attempts to cure them, account for 51% of all cancers diagnosed 
(Canadian Cancer Society’s Advisory Committee on Cancer Statistics 2015).  
Despite the “fame” of these cancers, there are others just as important, and yet not 
as well known. One of them being the appearance of a cancerous mass in the brain, or a 
brain tumor. There was an estimated 3000 new cases of brain cancer within Canada in 2015 
(Canadian Cancer Society’s Advisory Committee on Cancer Statistics 2015). In general, 
brain cancer is known to be a leading cause of cancer related deaths (Soffietti et al. 2002; 
Van Den Bent 2003). Stats Canada ranks it as the 9th highest mortality rate related to cancer 
in general (Canadian Cancer Society’s Advisory Committee on Cancer Statistics 2015). A 
tumor within the brain or, in general the central nervous system (CNS), may cause various 
symptoms in patients. The list of symptoms is long, since they vary greatly depending on 
the location of the tumor. Some of these symptoms may be prolonged headaches, seizures 
and impairment of the motor and sensory functions (Gril et al. 2010). Thus, their impact on 
the individual is quite dramatic. 
The most common brain tumors are those that grow rapidly and are metastatic in 
origin. Known as brain metastases, or secondary brain cancer, they develop in individuals 
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already diagnosed with cancer. The fraction of cancer patients who develop a brain 
metastases have been considered to be 20-40% of cancer patients (Arnold & Patchell 2001; 
Soffietti et al. 2002). 40-50% of brain metastases stem from primary lung cancers, whereas 
another 20-30% arise from breast cancers (Patel & Mehta 2007; Gril et al. 2010). However, 
these fractions may rise due to advanced neuroimaging techniques. The number of 
diagnosed brain metastases outweighs the number of primary brain tumors by a 10:1 ratio 
(Gril et al. 2010; Fortin 2012). 
Alternatively, a primary brain cancer stems from brain tissue and develops as a 
cancer without any requirement of another pre-existing cancer. There are at least a hundred 
and twenty different specific types of tumors that may develop in the brain, such as 
anaplastic oligodendroglioma and gliosarcoma (Brain Tumour Foundation of Canada. 
2015). However, even though there is a wide range of brain tumors, the most prominent 
one is the glioblastoma (GBM). Also known as glioblastoma multiforme, it can arise in two 
different ways; primary GBM known as de novo GBM, or secondary GBM. De novo GBM 
is considered to be the most common and aggressive primary brain tumor (Mashimo et al. 
2014; Crespo et al. 2015). It constitutes about 95 percent of all GBM cases or about 23 
percent of all diagnosed primary brain tumors (Ohgaki & Kleihues 2007; Najafi et al. 2012; 
Sturm et al. 2014; Zadran et al. 2014). They have been classified by the World Health 
Organization (WHO) as grade IV astrocytomas (Louis & Ohgaki 2007; Crespo et al. 2015). 
The expected survival duration for patients suffering from ‘primary’ GBM rarely exceeds 
five years, where the average survival rate is one year with a median of 16 months (Krex et 
al. 2007; Mashimo et al. 2014; Zadran et al. 2014). As for ‘secondary’ GBM, it arises from 
lower-grade tumors, which would consist of WHO’s grade II and grade III, which are 
astrocytomas and anaplastic astrocytomas respectively, and only represent the remaining 
5% of GBM cases (Ohgaki & Kleihues 2007; Sturm et al. 2014). Therefore, ‘primary’ 
GBMs are considered to be most prominent within GBM studies. 
Various studies have focused on GBMs with a variety of outcomes. One focus of 
study pertains to their epigenetic constitution. Epigenetics is a heritable change, which may 
consist of an addition of a chemical group on DNA that can affect gene expression without 
directly changing the DNA sequence (Hartl 2011; Hattori & Ushijima 2014). MicroRNA 
and histone alkylation can also carry epigenetic effects on gene expression (Pfeifer, Gerd. 
  
3 
3 
P.Hahn 2014). Furthermore, DNA methylation is an epigenetic change, which can affect 
gene expression. DNA methylation occurs predominantly on cytosines (C) that contain a 
specific chemical bond known as a CpG dinucleotide (Marx 2012). A large number of CpG 
dinucleotides are in clusters known as CpG islands, where many of these islands a grouped 
in gene control regions, particularly regulatory and promotor regions (Sidiropoulos et al. 
2005). 
The methylation of DNA is an enzymatic process that is performed by DNA 
methyltransferases (DNMTs), which catalyzes the transfer of the methyl chemical group 
onto the fifth position of C (Figure 1) (Robertson 2001; Grassi 2003; Kim et al. 2012). 
There are three DNMT enzymes that can perform this reaction: DNMT1, DNMT3A and 
DNMT3B. DNMT1 functions to maintain DNA methylation patterns. It has the capability 
to methylate DNA during DNA replication to ensure the same methylation pattern on the 
daughter strand as found on the original DNA strand (Goffin 2002). DNMT1 is found to be 
in higher abundance than DNMT3A and DNMT3B, but the latter are no less important. 
Both DNMT3A and DNMT3B have the ability to methylate DNA de novo, because of their 
affinity for hemi-methylated or non-methylated DNA (Goffin 2002; Kim et al. 2012). It is 
important to note that hemi-methylated DNA is when only one of the DNA strands in the 
double helix is methylated and the other is not. In this state, the single methylation still 
carries the same DNA activity as unmethylated DNA (Deobagkar et al. 1990). Furthermore, 
hemi-methylated DNA can lead to de novo methylation as mentioned previously, but also 
in certain circumstances, it can maintain DNA methylation by recruiting DNMT1 
(Nishiyama et al. 2013). 
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Figure 1. Cytosine Methylation 
Cytosine methylation consists of the addition of a methyl chemical group on the fifth 
carbon of the cytosine ring by either DNMT1, DNMT3A or DNMT3B, thus creating 5mC. 
 
Irrespective of which DNMT implicated in the addition of a methyl group to 
cytosine, it has been found to create a stable chemical modification known as 5-
methylcytosine (5mC) (Bird 2001) (Figure 1). The creation of this fifth DNA base, now 
allows a transcriptional repression capacity within eukaryotes without affecting the genetic 
code (Klose & Bird 2006). Alternatively, histone alkylation may also carry an epigenetic 
effect on gene expression (Feil & Fraga 2012). In the case of 5mC, it has the capability to 
silence gene expression, thus giving it important roles in genome stability, differentiation 
and development (Baylin & Jones 2011; Nabel, Manning, et al. 2012; Robertson et al. 
2014). Therefore, 5mC is a prominent subject in epigenetic research.  
However, since 2009, a new epigenetic mark has attained much attention. 5-
Hydroxymethylcytosine (5hmC) may have been mentioned as early as 1972, but it was in 
2009, with the simultaneous discovery of high amounts of 5mC in Purkinje neurons and 
characterization of the ten-eleven translocation (TET) enzyme family, that 5hmC was 
officially accepted as a new epigenetic mark, thus becoming the sixth DNA base (Penn et 
al. 1972; Kriaucionis & Heintz 2009; Tahiliani et al. 2009). TET is a part of the family of 
α-ketoglutarate (α-KG) and Fe(II)-dependent dioxygenases (Tahiliani et al. 2009; Ito et al. 
2010). The α-KG, required for TET activity, is created by isocitrate dehydrogenase (IDH1 
& IDH2) proteins through oxidation and decarboxylation of isocitrate (Xu et al. 2011). 
5mC has been shown to be converted to 5hmC by oxidation mediated by the TET enzymes 
(Tahiliani et al. 2009) (Figure 2). The specific roles of 5hmC have been greatly debated 
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amongst scientists. The widely accepted main role of 5hmC is as an important intermediate 
in the DNA demethylation pathway (Tahiliani et al. 2009; Ito et al. 2011).  
 
 
 
 
 
 
 
 
Figure 2. Conversion of 5mC to 5hmC 
The primary step in the oxidation pathway performed by TET enzymes consist of the 
oxidation of the methyl group on 5mC creating 5hmC.  
 
The function of the DNA demethylation pathway is to remove the methyl group 
from the cytosine ring of 5mC, thus restoring cytosine. This process allows the reactivation 
of genes that were formerly supressed with the presence of 5mC. There are two versions of 
demethylation activity that can take place; passive and active demethylation. Passive 
demethylation depends on the down regulation of the DNMT1 enzyme activity. With its 
activity reduced, the maintenance of the methylation pattern is no longer kept up during 
DNA replication. Therefore, the levels of DNA methylation gradually decrease with every 
replication through passive dilution (Lu et al. 2015). Furthermore, passive demethylation 
may occur with 5hmC. In these circumstances, 5hmC is not recognized by DNMT1, which 
would prevent the maintenance of DNA methylation (Stroud et al. 2011; Ito et al. 2010). 
Therefore, passive demethylation may lead to a reduction in 5mC and 5hmC. 
On the other hand, active demethylation requires the presence of various enzymes. 
A key player in the active demethylation pathway is the TET enzyme family. To initiate the 
demethylation process, as mentioned previously, TET would oxidize 5mC to 5hmC 
(Tahiliani et al. 2009; Koh et al. 2011). However, the TET oxidation process is a sequential 
procedure that does not stop at the initial formation of 5hmC. TET can further oxidize 
5hmC creating 5-formylcytosine (5fC) finishing with its conversion to 5-carboxylcytosine 
(5caC) (Gu et al. 2011; Inoue et al. 2011; Ito et al. 2011; Faggio et al. 2011) (Figure 3).  
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Figure 3. TET Oxidative Process 
The oxidation pathway performed by TET enzymes consist of the oxidation of the methyl 
group on 5mC creating 5hmC. When further oxidized, 5hmC converts to 5fC to then finally 
become 5caC. 
 
However, the extent of the TET enzyme’s implication comes to an end with 5caC. 
TET does not have the capabilities to bring the demethylation pathway to a full closure by 
reinstating cytosine. Therefore, there are other enzymes that are recruited to fulfill this final 
task. These enzymes belong to the family of base excision repair enzymes, whose well 
known function is to repair oxidative and alkylation damage to DNA. Base excision repair 
(BER) involves the initial cleavage of the N-glycosidic and phosphodiester bonds, followed 
by removal of the abasic site, nucleotide addition by DNA polymerase and ligation. 
Thereby, 5hmC, 5fC and 5caC, and related modifications, may be removed from the 
genome and replaced with non-modified cytosine during base excision repair. With 5hmC, 
it is also possible to form 5-hydroxymethyluracil (5hmU) as an intermediate between 5hmC 
and cytosine through a deamination process. Generally, 5hmU is known as an oxidative 
product of thymine (T) created by reactive oxygen species (ROS) (Mouret et al. 1991). 
5HmU opposite A in double stranded DNA is removed by BER enzyme known as single-
strand selective monofunctional uracil DNA glycosylase 1 (SMUG1) (Abdel-Fatah et al. 
2013). 
The exogenous and endogenous factors, which tend to promote the development of 
cancer, are known to create oxidative stress in cells (Irigaray et al. 2007).  Oxidative stress, 
in a general point of view, generates a constant amount of ROS as a result of normal 
mitochondrial electron transport that maintains cellular ATP levels. Under certain 
circumstances, there is an increase in ROS levels due to partial decoupling of electron 
transport or to activate NADPH oxidase and other cellular process during inflammation 
(Barciszewska et al. 2014). With high levels of ROS present, normal mediators to stabilize 
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and remove these oxidative agents become overwhelmed. Therefore, it may lead to the 
creation of various DNA damage, where some of them may approach the levels of 
epigenetic marks, such as 5hmC and 5fC. In general, the impact on DNA is directed in 
particular to guanine (G), leading to the creation of 8-oxo-7,8-dihydroguanine (8-oxo-G) 
(Mikkelsen et al. 2009; Volle et al. 2011). 8-oxo-G damage in DNA can challenge DNA 
repair processes and lead to mutations (G to T transversion) if the damage is not promptly 
repaired by the appropriate BER enzymes. The level of 8-oxo-G has been associated with 
an increase in the formation amyloid deposits within the brain, thus possibly accelerating 
the progression of Alzheimer’s disease (Davies 2000; Cencioni et al. 2013). Furthermore, 
oxidative stress tends to affect DNA methylation patterns, which may lead to other health 
problems such as increased chances of heart failure (North & Sinclari 2012).  
The accumulation of 5hmU in cellular DNA may be due to either 5hmC 
deamination or thymine oxidation. Interestingly, 5hmU is also formed by the enzymatic 
oxidation of thymine in DNA by TET enzymes (Pfaffeneder et al. 2014; Robertson et al. 
2014).  Albeit, this reaction is much slower than the one with 5mC. Thus, the primary 
activity of TET would be directed on 5mC, but the dioxygenase activity of TET is not 
exclusive to cytosine derivatives.  
As a potential pathway in the removal of 5hmC from DNA, 5hmC may undergo 
enzymatic deamination by activation-induced deaminase (AID) or apolipoprotein B 
mRNA-editing enzyme complex (APOBEC) (Nabel, Jia, et al. 2012; Burns et al. 2013; 
Robertson et al. 2014). The deamination performed by either enzyme leads to the 
problematic formation of a mismatch now present within the DNA similar to a T:G 
basepair. Therefore, the base excision repair (BER) pathway comes into play. One of the 
BER enzymes that would be used is thymidine DNA glycosylase (TDG), which can replace 
5hmU with a non-modified cytosine (Morgan et al. 2004; Cortellino et al. 2011; Maiti & 
Drohat 2011; Nabel, Jia, et al. 2012) (Figure 4). The implications of TDG can, also, extend 
to 5fC and 5caC. It should be noted that TDG does not act on 5hmC:G basepairs, but only 
on subsequently oxidized forms (5fC or 5CaC) and the deaminated form, 5hmU. The 
excision of these modifications does not require an intermediate molecule. Indeed, they are 
preferentially excised by the TDG enzyme, since the enzyme has a higher affinity for these 
5hmU:G basepairs than the T:G basepairs (Maiti & Drohat 2011) (Figure 4). Therefore, 
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with the addition of AID/APOBEC and BER/TDG, the deamination pathway, initiated by 
TET, would come to a full closure. Thus, DNA demethylation is a dynamic pathway. 
Figure 4. Base Excision Repair Mechanism 
Base excision repair (BER) pathway is used in the demethylation pathway to reinstate 
cytosine within DNA. An enzyme used for this mechanism is TDG. It act directly on 5fC 
and 5caC. However, 5hmC must be deaminated by to 5hmU before BER can function.  
 
5HmC plays a primary role within the demethylation pathway. It is believed that 
5hmC is an epigenetic mark because it plays a role in gene regulation similar to its 
predecessor 5mC. 5HmC has been found to be highly concentrated within enhancer and 
gene bodies although they are also prominent in promotor regions (Stroud et al. 2011). This 
may be related to the removal of 5mC that supresses gene expression within these areas. 
Therefore, enzymatic oxidation of 5mC can activate genes that were previously silenced by 
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high levels of 5hmC in these regions. However, many more studies will be necessary to 
understand the full impact of 5hmC in gene regulation (Colquitt et al. 2013; Shen & Zhang 
2013). One study has demonstrated that 5hmC does have a gene regulation capacity, but 
opposite to that of 5mC. It was shown that, when there is a reduction of 5hmC, gene 
expression is reduced, and when there is an increase in 5hmC levels, expression increases 
(Jin, Wu, et al. 2011; Colquitt et al. 2013). Colquitt and co-workers have demonstrated this 
hypothesis using methylated immunoprecipitation to assess 5hmC/5mC ratios, and 
correlated these with the immunoprecipitation of Olfacotry marker protein expressed in 
horizontal basal cells, Neurogenin1 expressed in globose basal cells and Intercellular 
Adhesion Molecule 1 expressed in mature olfactory sensory neurons, where each cell types 
represented a step of the three stages in neurodevelopment respectively (Colquitt et al. 
2013). Hence, 5hmC is a key intermediate in DNA demethylation, but if present it can also 
enhance gene expression. However, there is still uncertainty of the molecule’s possible 
alternate roles that it may possess. 
Genomic 5hmC is found in cells of all tissues of the human body. However, its 
levels differ greatly from one tissue to another. For example, the spleen has levels of 5hmC 
ranging from 0.03-0.06% of C, whereas the heart has levels of 0.15-0.17% of C (Globisch 
et al. 2010). However, it is well established that 5hmC levels are highest within the CNS, in 
particular in the brain, which has levels ranging from 0.4-0.7% of C (Kriaucionis & Heintz 
2009; Globisch et al. 2010; Li & Liu 2011). Within the brain itself, levels also vary 
amongst the different regions. Several studies have found that the levels of 5hmC are most 
abundant in the cortex (Feng et al. 2010; Globisch et al. 2010; Szwagierczak et al. 2010; 
Jin, Wu, et al. 2011; Li & Liu 2011). Nevertheless, the specific functional purpose 
explaining the high levels of 5hmC in the CNS is relatively unknown.  
 Oddly enough, the levels of 5hmC found in various tissues becomes greatly altered 
during the development of a tumor. The occurrence of hypohydroxymethylation, a 
reduction in hydroxymethylation levels (5hmC), is a key feature of cancer. Several studies 
have demonstrated this tendency in cancer (Kudo et al. 2012; Gambichler et al. 2013). For 
example, levels of 5hmC present in colon cancer tissue are 4-fold lower in comparison with 
normal tissue (Li & Liu 2011). Similar out-comes can be said for the development of brain 
tumors. In extreme cases, the levels of 5hmC are reduced by as much as 30-fold within a 
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brain tumor (Jin et al. 2011). One research group compared GBM cells to cells of normal 
brain tissue obtained from a brain bank. The results were staggering. Kraus and his 
associates estimated the percentage of 5hmC in cells that stain positive to antibodies toward 
5hmC was 73.5%, 45.2% and 50.1% in healthy cortex, cerebral white matter and cerebellar 
cortex, respectively. Using an antibody approach to detect 5hmC, they found only 2.23% of 
5hmC positive cells in GBM tissue (Kraus, Kolck, et al. 2015). These results magnify the 
dramatic reduction of 5hmC within GBMs. Furthermore, various studies have demonstrated 
that not only is 5hmC reduced in cancer, but that these levels may also further decrease as 
the cancer progresses to a more aggressive form (Kudo et al. 2012; Orr et al. 2012; Takai et 
al. 2014).  
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Problematic 
The downregulation of TET enzymes in cancer leading to a reduction in 5hmC is a 
phenomenon observed in various malignancies (Yang et al. 2013; Gambichler et al. 2013; 
C. Liu et al. 2013). Hence, it may be a partial cause to the progression of certain cancers. 
Also, some mutations in isocitrate dehydrogenase-1 (IDH1) leading to a decline in TET 
enzyme activity, would inadvertently lower 5hmC levels as well (Waha et al. 2012).  
However, the true mechanisms explaining a significant reduction of 5hmC during the 
development and growth of GBMs, in particular, are still unclear. 
Objectives 
Objective #1 (Article, main project) 
The primary goal of this research was to modulate the levels of 5mC and related modified 
bases (5hmC and 5fC) within cell culture that was incubated with these modified 
nucleosides. Using LC-MS/MS analysis the ratio of 5mC, 5hmC and 5fC per 100 cytosine 
bases allows a comparison of normal cellular levels of these modified nucleosides versus 
the levels in the cells incubated with these cytosine modifications. The final outcome would 
allow an insight in the demethylation pathway mediated by TET, which connects 5mC, 
5hmC and 5fC together. Thus, any unusual enzymatic activity may be noted. 
Objective #2 (Secondary Project) 
Within brain tumors, the aberrant levels of 5hmC have been noted often. However, a deeper 
analysis of not only 5mC, 5hmC, and 5fC, but also the related deaminated derivatives 
(5hmU and 5fU) could lead to a more profound understanding of the epigenome of brain 
cancer. LC-MS/MS analysis of these modified nucleoside levels within low grade 
astrocytomas (grade II and III) and GBM (grade IV) tumors would demonstrate any 
variations in their levels and comparisons between the two tumor types would deepen the 
understanding of how GBMs epigenetically differ from its fellow brain tumors. 
Hypotheses 
Hypothesis #1 
During the cellular incubation experiments, it is expected that 5mC, 5hmC and 5fC would 
be readily incorporated into the genomic DNA. Hence, the levels of these modifications 
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would increase. Therefore, with their initial levels higher than normal, it was anticipated 
that the other molecules further down the demethylation pathway would increase as well. 
Hypothesis #2 
Whilst comparing the levels of 5mC and its potential intermediates within low grade 
astrocytomas (grade II and III) and GBM (grade IV) tumors, we expected to find the 
signature low levels of 5hmC as it has been reported in various studies. However, we may 
expect the levels of the alternate 5mC modifications to be abnormal, for example, levels of 
5fC may be higher or those of 5hmU due to aberrant enzymatic activity in the 
demethylation pathway.  
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ARTICLE 1 
Modulation of genomic 5-hydroxymethylcytosine and its demethylation derivatives 
upon incubation in cell culture with related modified nucleosides. 
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Prologue: For the cellular experiments, I performed the 5hmC, 5fC and 5hmC + dTHU. 
Also, I performed the DNA extraction, digestion and the subsequent LC-MS/MS analysis. 
Furthermore, I wrote the initial draft of the manuscript. Laurent-Olivier Roy taught me the 
necessary cell culture technique for cellular incubation with the modified nucleosides. In 
addition, he has performed the toxicity assay and the 5mC cell incubation. Dr. David Fortin 
allowed me access to his level 2 laboratory for the cell studies along with kindly providing 
all required materials, i.e. cell media, and the U87 cell line. Finally, Prof. J. Richard 
Wagner taught me the use of the LC-MS/MS, and being my supervisor, he also helped me 
in the revision of the manuscript prior to submission. 
 
Résumé : 5-Hydroxyméthylcytosine (5hmC) est une marque épigénétique nouvellement 
caractérisé. Celle-ci est le résultat de l’oxydation enzymatique de la 5-méthylcytosine 
(5mC) dans l’ADN par la famille des enzymes ten-eleven translocation (TET). Cet 
évènement peut expliquer une régulation diversifiée de certains gènes. 5HmC est présent 
dans tous les tissus de mammifères, mais ses niveaux sont plus élevés dans le cerveau. 
Dans le développement et la croissance de nombreux cancers humain, particulièrement le 
cancer du cerveau de niveau maligne, les niveaux de 5hmC sont largement réduits par des 
mécanismes encore inconnus. Dans l’ADN des cellules U87 en culture, les niveaux de 
5hmC, ainsi que plusieurs modifications correspondantes (5mC, 5-formylcytosine (5fC), 5-
hydroxyméthyluracile (5hmU) et 5-formylcytosine (5fU)), sont suivi de près par LC-
MS/MS lors d’une incubation avec 5mC, 5hmC et 5fC nucléosides purifiés. Nos résultats 
démontrent qu’il est possible d’augmenter le niveau génomique de 5hmC dans l’ADN 
cellulaire lors d’une incubation avec le nucléoside 5hmC, mais l’augmentation est faible 
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(environ 1-2 fois). Étrangement, l’incubation avec 5hmC a également conduit à une 
réduction du niveau d’origine génomique de 5fC. Cependant, durant l’incubation avec 
5hmC ou 5fC, il y a une incorporation massive des dérivés d’uracile (5hmU et 5fU). Ce qui 
est intéressant, ceux-ci sont maintenus à des niveaux élevés après 3 jours d’incubation. 
Toutefois, lorsque les cellules ont été co-incubées avec un inhibiteur de l’activité de 
cytosine désaminase, 3,4,5,6-tétrahydro-2’-déoxyuridine, l’incorporation initiale de 5hmU 
dans l’ADN cellulaire a été réduite de 65%. Ces résultats indiquent que la désamination de 
5hmC bloque son incorporation dans l’ADN cellulaire tout en conduisant à l’accumulation 
du dérivé 5hmU correspondant. Cette voie peut expliquer la présence de niveau élevé de 
5hmU dans l’ADN cellulaire dans certaines conditions.  
  
15 
15 
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Abstract 
 5-Hydroxymethylcytosine (5hmC) is a newly characterized epigenetic mark arising 
from the enzymatic oxidation of 5-methylcytosine (5mC) in DNA by the ten-eleven 
translocation (TET) enzyme family. This event can explain differential regulation of certain 
genes. 5HmC is present in all mammalian tissues, but its levels are the highest within the 
brain. In the development and growth of many human cancers, particularly malignant brain 
cancer, the levels of 5hmC are greatly reduced due to as yet to unidentified mechanisms. 
Here, the levels of 5hmC as well as several related modifications (5mC, 5-formylcytosine 
(5fC), 5-hydroxymethyluracil (5hmU) and 5-formyluracil (5fU)) in the DNA of U87 cells 
in culture was monitored by LC-MS/MS upon incubation with purified 5mC, 5hmC and 
5fC nucleosides. Our results demonstrate that it is possible to increase the genomic level of 
5hmC in cellular DNA upon incubation with 5hmC nucleoside albeit the increase is modest 
(about 1-2 fold). Interestingly, incubation with 5hmC also led to a reduction in the level of 
genomic 5fC. Most strikingly, however, incubation with either 5hmC or 5fC led to massive 
incorporation of the corresponding uracil derivatives of 5hmC and 5fC, i.e., 5hmU and 5fU, 
respectively. The steady state level of 5hmU and 5fU remained elevated after 3 days 
incubation. The initial incorporation of 5hmU into cellular DNA was reduced by 65% but 
not entirely when cells were co-incubated with an inhibitor of cytosine deaminase activity, 
3,4,5,6-tetrahydro-2’-deoxyuridine. These results indicate that the deamination of 5hmC 
blocks its incorporation into cellular DNA while leading to the accumulation of the 
corresponding 5hmU derivative into DNA. This pathway may explain the presence of high 
levels of 5hmU in cellular DNA under certain conditions. 
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Introduction  
The methylation of DNA by DNA methyltransferases (DNMTs) converts cytosine 
to 5-methycytosine (5mC), predominantly within CpG dinucleotides leading to 60-90% 
methylation of these sites in mammals (1,2). Cytosine methylation is a well-known 
epigenetic mark that regulates the expression of genes during development and maintains 
genetic stability thereafter (3,4). Although the presence of 5-hydroxymethylcytosine 
(5hmC) was reported in the 1970’s (5,6), this modification was only recognized as a novel 
epigenetic mark related to 5mC in 2009 (7,8). 5HmC arises from the enzymatic oxidation 
of 5mC by ten-eleven translocation (TET 1-3), a family of α–ketoglutarate (α-KG) and 
Fe(II)-dependent dioxygenases (8–10). The oxidation of 5mC to 5hmC is the initial step in 
the demethylation pathway mediated by TET, which ultimately converts 5mC back to 
cytosine. In this way, TET can directly alter gene regulation by reversing the effects of 
species and tissue specific gene methylation. In comparison to 5mC, 5hmC also 
accumulates to relatively high levels in the genome, displays a different distribution in the 
genome, and possesses a unique set of DNA and protein binding partners (11,12). A large 
proportion of 5hmC in the brain lies in gene-bodies (13–15) with substantial accumulation 
of 5hmC at non-CpG sites (16). Indeed, 5hmC appears to promote expression or act as a 
transition state between active and non-actively transcribed genes (15,17–19). 
The mechanism of active demethylation from 5hmC to cytosine is not clear. TET 
enzymes have the ability to perform iterative oxidation of 5mC, thereby generating 5hmC 
as well as further oxidation products: 5-formylcytosine (5fC) and 5-carboxycytosine (5caC) 
(10). The latter two modifications are substrates for thymine DNA glycosylase (TDG), 
which has been implicated in the demethylation of 5mC (10,20–23). An animal knockout of 
TDG is also lethal at early stages of development (24,25). Recently, TDG, TET and DNA 
containing 5mC was shown to form a tight complex and thereby transform 5mC to cytosine 
in association with base excision repair (26). Alternative mechanisms of demethylation 
have been proposed. Uracil-DNA glycosylase UNG2 is implicated in the removal of 5caC, 
specifically activating the transcription of a methylation-silenced reporter gene (27). 
Finally, several groups have proposed the deamination of 5hmC to 5hmU as an initial step 
in demethylation by activation induced deaminase and apolipoprotein B mRNA-editing 
enzyme complex family of cytidine deaminases (AID/APOBEC) (28,29). The co-
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expression of both TET1 and AID/APOBEC promoted the demethylation of 5hmC in 
cultured cells and adult mouse brain (21). Following deamination, 5hmU:G mispairs can be 
repaired by single-strand-specific mono-functional uracil DNA glycosylase 1 (SMUG), 
methyl binding domain protein 2 (MBD2) and TDG (30). Deamination was shown to 
amplify the removal of 5mC in densely methylated CpG loci by long patch BER and non-
canonical mismatch repair processes (31). A functional role of AID deaminases in 5mC 
demethylation though has been questioned because of the lack of adverse effects of AID-
deficiency during development in mice and humans (32,33) and the absence of 5hmU at 
potential sites of 5hmU-G mismatches in genomic DNA (34,35). 
The relatively high level of 5hmC in the brain compared to other tissues points to an 
important function of this epigenetic mark in the central nervous system possibly as a 
means to enhance brain plasticity (36–38). Numerous studies have reported changes in the 
global level and distribution of 5hmC in the genome with the onset and pathology of 
neurological diseases (34). During the development of malignant brain tumors, the levels of 
5hmC have been reported to fall dramatically as much as 30-fold in extreme cases (37). 
Furthermore, changes in the levels of 5mC and 5hmC have been correlated with the 
development and growth of glioblastoma, the staging of tumor progression, and patient 
survival (39). The underlying mechanisms for the reduction of 5hmC levels in brain cancer 
remain largely unknown. In an attempt to better understand the mechanism of 5mC 
demethylation, we have incubated immortalized human glioblastoma cells in culture with 
5mC, 5hmC and 5fC as modified nucleosides. Our results indicate that the modified 
nucleosides are taken up into cells but that they are not directly incorporated into cellular 
DNA; rather they undergo deamination to the corresponding uracil derivatives that are 
efficiently incorporated into DNA. 
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Methods and Materials 
Cell Culture and Treatment 
U-87 MG cells (human glioblastoma, ATCC® - HTB-14) were cultured in the 
presence of 5% CO2 at 37°C with Eagle’s Minimum Essential Medium (EMEM) 
supplemented with 10% Fetal Bovine Serum (FBS), 1mM of both sodium pyruvate and 
non-essential amino acids, and penicillin and streptomycin (100UI/mL - 1× 
penicillin/streptomycin). Incubations with 5mC, 5hmC, or 5fC were carried out at a 
concentration of 36µM. Cells were collected usually after three time points: 0h, 24h 48h 
and 96h. The concentration of 3,4,5,6-tetrahydro-2’-deoxyuridine (dTHU) used in co-
incubation experiments was 100-400µM. Cells were detached using 0.05% trypsin-EDTA, 
centrifuged and washed with phosphate buffered saline (PBS). 
Toxicity 
The toxicity of modified nucleosides was examined for U87 cells by the addition of 
5mC, 5hmC, and 5fC, 5hmU and 5fU (0-200µM). The compounds were dissolved in water 
and filtered through a 0.22 micron filter to sterilize the solution before addition to cells in 
culture medium. After treatment, the surviving fraction was determined using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) viability/cytotoxicity assay. 
Briefly, 7500 cells/100µL/well were seeded in 96-well plates and allowed to adhere 
overnight. The culture medium was removed, cells were washed with PBS, and phenol-red 
free culture medium containing various concentrations of compounds was added. Ten 
µL/well of MTT reagent (5mg/mL) was added and the plate was incubated at 37ºC for 4h 
with light stirring. Then, 65µL of medium/well was withdrawn followed by the addition of 
50µL/well of Triton X-100: isopropanol (1:10 ratio). The plate was returned at 37ºC for 4h 
with moderate/high stirring. Cell survival was estimated by the absorption at 570nm with a 
wavelength correction at 690nm using a PowerWave×340 and the KC junior software (Bio-
Tek instruments). 
DNA Extraction  
Cell pellets containing ~1 million cells were suspended in extraction buffer (10mM 
Tris-Cl, 5mM EDTA-Na2 and 0.10mM desferrioxamine, pH 8.0) and sodium dodecyl 
sulfate was added to give a final concentration of 1%. Cell lysis was performed by two 
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freeze-thaw cycles with liquid nitrogen. RNA was digested in the cell lysis mixture by the 
addition of 20µL of a freshly prepared solution RNase solution (Sigma R6513; 1mg/mL in 
10mM Tris-Cl, 1mM EDTA-Na2, 0.1mM desferrioxamine, pH 8.0). Subsequently, protein 
was broken down by the addition of a 15µL solution of a freshly prepared solution of 
Qiagen Protease (30AU) No. 19157; 1mg/mL concentration dissolved in Tris-Cl buffer, pH 
7.5), which was incubated for 2h in a water bath at 37°C with vortexing every 20 min. 
Finally, DNA was precipitated from the mixture by the addition of 600µL of a saturated 
solution of NaI solution (7.6M NaI, 40mM Tris-Cl, 20mM EDTA-Na2 and 0.1mM 
desferrioxamine), followed by the addition of 1mL of 2-propanol. The Eppendorf tube was 
inverted by hand until the aqueous and isopropanol phases merged together. To optimize 
the precipitation of DNA, the sample was placed in the freezer overnight at -10ºC. DNA 
was precipitated by centrifugation for 30 min at 4°C, and the supernatant was removed and 
discarded. The DNA pellet was washed twice, first with a solution 50% 2-propanol in 
water, and then with a solution of 70% ethanol in water. Each wash was followed by 
centrifugation at 10,000g for 10 min. The DNA pellet was dried by turning them upside 
down on a paper towel in ambient air for 30 min.  
DNA Digestion 
DNA pellets were dissolved in water containing desferrioxamine (0.1mM) and 5-
hydroxycytosine (10µM) to prevent DNA artificial oxidation. Labeled internal standards 
was added from a standard mixture (5µL) containing 5mC (30μM), 5hmC (0.2μM), 5fC 
(0.2μM), 5hmU (0.5μM), 5fU (0.5μM) and 8-oxo-7,8-dihydro-2’-deoxyguanosine (8oxoG; 
0.2μM). The digestion of DNA to its component nucleosides was accomplished in two 
steps. First, we added 5µL of 50mM sodium acetate buffer (pH 5.0) and 5µL of a stock 
solution of P1 nuclease (Sigma N8630; 1U/µL concentration in 50mM acetate buffer, pH 
5.0). The mixture was incubated at 50˚C for 30 min. In a second step, we added 10μL of 
Tris-Cl buffer (250mM) and 5µL of snake venom phosphodiesterease (Sigma P3134; 0.002 
U/µL concentration in 50mM Tris-Cl, pH 8.0) plus 5μL of alkaline phosphatase (calf 
intestine, Roche Diagnostics, 10713023001; 1U/µL in buffer provided by the 
manufacturer). The samples were incubated at 37°C for 60 min. Finally, 10μL of 0.22M 
phosphoric acid and 40µL of chloroform were added. The sample was briefly vortexed and 
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centrifuged for 10 min. The aqueous phase containing enzymatically hydrolyzed DNA was 
removed and stored at -20ºC before analysis. 
LC-MS/MS analysis 
The analysis of modified nucleosides was carried out using a HPLC system 
(Shimadzu) connected to a tandem MS instrument (API-3000, AB-Sciex). The 
chromatographic separation was achieved with an AcclaimTM PolarAdvantage II C18 
(2.1mm x 250mm, 3µm) column maintained at 30°C. The modified nucleosides eluted 
from a gradient of ammonium formate buffer (5mM, pH 5.0) and 90% acetonitrile that 
started at 10% and increased to 30% acetonitrile within 15 min at a constant flow rate of 
160μLmin-1.  Twenty µL injection volumes from a total volume of 90µL for each sample 
were employed. The MS parameters were optimized for the detection of each modified 
nucleosides as reported previously (40). Data collection and peak integration were 
performed using Analyst 6.2 software (AB-Sciex). The concentration of modified 
nucleosides was calculated from the ratio of integration areas obtained from the natural and 
corresponding isotopically labeled internal standard. The levels of the 5hmC, 5mC, 5fC and 
5hmU per 100 non-modified cytosine residues were calculated based on the concentration 
of modified nucleoside (MS analyses) and the concentration of non-modified nucleosides 
(C, T, G, A) monitored by UV absorption at 260nm. 
Statistics 
Statistics were performed using the student t-test. The parameters used were a 1 tail, 
type 2 t-test within excel 2013 program. 
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Results 
To assess the incorporation of modified nucleosides into cellular DNA, U87 cells 
were treated in culture medium with various nucleosides in combination with LC-MS/MS 
to measure the amount of 5mC, 5hmC and 5fC modifications in DNA (structures are shown 
in Fig 1). In addition, 5-hydoxymethyluracil (5hmU) and 5-formyluracil (5fU) were 
monitored to access the possibility that cytosine derivatives undergo deamination. 
Treatment of cells with either 5mC or 5fC showed minimal toxicity even at relatively high 
concentrations (200µM; <20% cell death; Fig 2). In contrast, treatment with 5hmC led to 
40%-50% cell death at 200µM. We chose to incubate cells with a concentration of 5mC, 
5hmC and 5fC of 36µM corresponding to no higher than 35% cell death for all three 
derivatives of 2’-deoxycytidine. The toxicity of the modified derivatives of 2’-
deoxyuridine, 5hmU and 5fU, was also examined; they showed greater toxicity than the 
corresponding 2’-deoxycytidine derivatives. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Structure of DNA methylation and demethylation intermediates. Cells were 
incubated with the nucleoside (structure attached to a 2-deoxyribose moiety) and the 
modifications were assessed in cellular DNA as the nucleoside by LC-MS/MS.  
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Fig. 2. Toxicity 5mC, 5hmC, 5fC, 5hmU and 5fU nucleosides toward U87 cells in 
culture. 
 
The percentage of endogenous 5mC to cytosine in the DNA of U87 cells was on 
average about 2%. Upon treatment with 36µM 5mC, there was no significant change in the 
level of 5mC in cellular DNA (Fig 3A). Upon incubation with 5mC nucleoside, the levels 
of 5hmC significantly decreased by 2.9-fold (p<0.05) to the levels observed in the control 
group (Fig 3B). Similar effects of 5mC incubation were also observed with the levels of 
5fC, where there levels diminished by 8.7-fold and remained 6.5-fold lower than at 0h 
(Figure 3C). Thus, both 5hmC and 5fC decreased in cellular DNA upon incubation of U87 
cells with 5mC nucleoside.  
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Next, we performed incubations with 5hmC nucleoside. The results showed a 
progressive increase of 5hmC in DNA giving a 1.9-fold increase after 96h incubation 
compared to the levels at initial and 24h incubation periods (Fig 4A). Interestingly, the 
levels of 5fC in DNA decreased at 48h (0.0065%) and remained low at longer times 
(0.014%) compared to the initial levels of 0.024% of 5fC per cytosine in DNA. A 
surprising level of incorporation was observed for the deamination product of 5hmC: 5hmU 
(Fig 4B). The amount of 5hmU in DNA increased from a basal level of 0.10% to 4.94% 
5hmU per cytosine (49-fold; p<0.01) within the first 24h of incubation. After 24h, the 
levels of 5hmU in cellular DNA decreased to about half, indicating removal of this 
modification as a function of incubation (Fig 4B). The levels of 5hmU in cellular DNA 
remained high at about 2% 5hmU per cytosine even after 96h.  
 
 
Fig. 3. Treatment of cells with 5mC. 
(A) Levels of 5mC in cellular DNA 
and (B) levels of 5hmC in cellular 
DNA (*p<0.05). Analysis represents 
the average of three independent cell 
experiments. 
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Fig. 4. Treatment of cells with 5hmC. (A) Levels of 5hmC in cellular DNA and (B) levels 
of 5hmU in cellular DNA. Error bars indicate the standard deviation from three 
independent cells experiments (*p<0.05; **p<0.01). 
 
Following incubation studies with 5mC and 5hmC, we turned our attention to 5fC 
nucleoside. For this modification, there was no variation in the percentages of either 5mC 
or 5hmC incorporation into cellular DNA. Likewise, the levels of 5fC did not increase 
during incubation (Fig 5A). However, the levels of its deaminated derivative, 5-
formyluracil (5fU) increased from nearly undetectable levels (~0%) to notably high levels 
of 0.25% within the first 48h of incubation (Fig 5B). The levels of incorporation of 5hmU 
into cellular DNA were about 20-fold higher than those observed for 5fU after exposure to 
the same concentration of 5hmC and 5fC, respectively (comparing Fig 4B and 5B). 
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Fig. 5. Treatment of cells with 5fC. (A) Levels of 5fC in cellular DNA and (B) levels of 
5fU in cellular DNA. Error bars indicate standard deviation from three independent cells 
experiments (*p<0.05; **p<0.01). 
 
Because 5hmU is generated from the deamination of 5hmC, we examined the effect 
of a well-known inhibitor of cytidine deamination activity, 3,4,5,6-tetrahydro-2’-
deoxyuridine (dTHU) (39–42). The inhibition of cytidine deaminase activity in U87 cells 
reached a plateau at concentrations of dTHU above 200µM. When cells were incubated 
with both 5hmC (36µM) and dTHU (200µM), the levels of 5hmC in cellular DNA 
increased from about 2 to 3.3% of 5hmC per cytosine (Fig 6A). This effect was very 
similar to our previous results using only 5hmC nucleoside (Fig 4A). The addition of both 
5hmC and dTHU also led to a substantial increase of 5hmU in cellular DNA within the 
same time frame (Fig 6B). A comparison of the effect of 5hmC with and without dTHU 
indicates that inhibition of cytidine deaminase activity by dTHU reduced the initial 
incorporation of 5hmU by about 65% at the 24h time point although the reduction was 
smaller at later time points.    
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Fig. 6. Treatment of cells with 5hmC in the presence of dTHU. (A) Levels of 5hmC in 
cellular DNA and (B) levels of 5hmU in cellular DNA. Error bars indicate standard 
deviation from three independent cells experiments (*p<0.05).  
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Discussion 
Numerous nucleoside derivatives are genotoxic because they resemble natural 
nucleic acids in structure and become incorporated into cellular DNA. For example, 5-aza-
2’-deoxycytidine and related nucleosides are taken up into cellular DNA, thereby inhibiting 
DNA methyltransferase activity, decreasing methylation and altering epigenetic gene 
regulation (43). Various halogenated derivatives of 2’-deoxycytidine and thymidine have 
been proposed as antiviral agents, anticancer drugs, as well as radiosensitizers due in part to 
their ability to accumulate in cellular DNA and interfere with transcription, replication and 
DNA repair (44–46). Nucleosides in cell culture can enter cells through nucleoside 
transporters. Once inside, the nucleosides can undergo phosphorylation to monophosphate 
and further to the di- and tri-phosphate forms by nucleic acid kinases for their subsequent 
incorporation into cellular DNA.  
In view of the role of 5mC in epigenetics, random incorporation of this nucleoside 
into the genome would likely be devastating. For this reason, the incorporation of 5mC into 
cellular DNA of mammalian cells does not occur to any significant extent either artificially, 
upon exposure to high concentrations of the nucleoside, or naturally, during the salvage of 
nucleotides arising from DNA degradation. Thus, there was no incorporation 5mC in the 
DNA of U87 cells upon incubation with 5mC nucleoside (Fig 3A). Two pathways appear to 
be responsible for blocking the uptake of 5mC into cellular DNA: 1) the inefficient 
phosphorylation of 5mC particularly from mono to diphosphate derivatives by nucleoside 
monophosphate kinases; 2) the presence of a robust cytosine deaminase activity (CDAs) 
that efficiently induces the deamination of 5mC to thymidine at the level of the nucleoside 
and mononucleotide (47). Interestingly, incubation of cells with 5hmC nucleoside resulted 
in an increase in the level of 5hmC in cellular DNA by about 2-fold (Fig 4A and Fig 6A). 
This effect may be explained by either an inductive effect of 5mC nucleoside on TET1/3 
activity that in turn converts 5mC to 5hmC or an inhibiting effect of 5mC nucleoside on the 
removal of 5hmC from DNA. Alternatively, the effect of 5mC may be due to an increase in 
the concentration of intracellular thymidine, as a result of the deamination of 5mC to 
thymidine by CDAs (48).  
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When cells were incubated in cell culture with 5hmC nucleoside, there was an 
increase in genomic 5hmC by about 1.5-fold. These results indicate that the blockade 
toward the incorporation of 5mC is somewhat alleviated for 5hmC compared to 5mC. It 
should be noted though that the triphosphate of 5hmC will be inserted essentially opposite 
any G during DNA polymerization, and thus, this method of insertion is not site-
specifically directed toward CpG dinucleotides. From our analysis, the level of several 
other modifications related to 5hmC was also determined by LC-MS/MS. In sharp contrast 
to 5hmC, the amount of 5hmU, the deamination product of 5hmC, ascended to 
extraordinarily high values from 0.1% of cytosine in control cells to 5% of cytosine in 
treated cells cytosine (50-fold). Indeed, the levels of 5hmU were higher than that of 
endogenous 5mC. To understand the origin of 5hmU in DNA, we investigated the 
involvement of cytosine deaminase activities (CDAs) by treating cells with 5hmC in the 
presence of a well-known inhibitor of CDAs (dTHU).  The addition of dTHU leads to the 
inhibition of both predominant types of CDA that are directed toward either nucleoside or 
monophosphate nucleotide substrates containing a cytosine moiety. Whereas dTHU inhibits 
CDAs at the nucleoside step, the phosphorylation of dTHU inside cells leads to 
phosphorylated dTHU that inhibits the deamination of nucleotides. Our results 
demonstrated a substantial decrease in the final level of 5hmU in cellular DNA treated with 
5hmC in the presence of dTHU (Fig 6). Thus, we conclude that the massive accumulation 
of 5hmU in cells treated with 5hmC arises from deamination of 5hmC to 5hmU at either 
the nucleoside or nucleotide level followed by subsequent phosphorylation and 
incorporation into cellular DNA. 
Several years ago, Boorstein and co-workers studied the incorporation of 5hmU into 
cellular DNA upon incubation of cells in culture with the nucleoside (49). They reported 
relatively high toxicity of 5hmU nucleoside when it was administered in cell culture to 
hamster V79 cells at concentrations between 0.1-1µM. The toxicity of 5fC in cell culture 
has also been reported at low concentrations for 5fU (50). In our experiments with 5hmC, 
the majority of U78 cells survived a treatment of as high as 36µM of 5hmC, indicating the 
5hmC is much less toxic than 5hmU when given in cell culture. Although the incorporation 
of 5hmU into V79 cells was limited by toxicity, the level of 5hmU obtained by incubation 
with 5hmU (8 per 100 thymine) was comparable to that obtained by incubation with 5hmC 
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(5 per 100 cytosine) after exposure to the same concentration of nucleoside for 24h (51). 
Thus, exposure of cells to either 5hmC or 5hmU leads to the incorporation of 5hmU into 
cellular DNA with approximately the same efficiency. This is very interesting because 
5hmU is much more toxic than 5hmC even though similar levels of incorporation of 5hmU 
are obtained for a given concentration. A possible explanation may include difference in the 
cell lines with respect DNA repair and ability to cope with high levels of DNA damage or 
alternative mechanisms of toxicity for 5hmU that are bypassed upon incubation with 5hmC. 
Recent studies suggest that 5hmU is also an epigenetic mark (52). The levels of 
5hmU are notably higher in the DNA of mouse embryonic stem cells and human 
spermatocytes compared to somatic cells (33,53). The levels of 5hmU fluctuate with the 
expression of TET, they are more closely correlated with the levels of 5hmC than with 
those of 8oxoG, an indicator of oxidative DNA damage, and sequences containing 5hmU 
specifically bind chromatin remodeling proteins and transcription factors (33). These 
studies suggest that TET enzymes can also oxidize T to 5hmU in the genome in addition to 
its main role as a mediator of 5mC oxidation to 5hmC. In the present work, we show that 
5hmU nucleoside is efficiently incorporated into cellular DNA when cells are incubated in 
culture with 5hmC nucleoside. Thus, it is reasonable to propose an alternative scenario to 
explain the presence of 5hmU in cellular DNA, which involves the turnover of cellular 
DNA containing 5hmC during either cell division or DNA repair followed by deamination 
of 5hmC to 5hmU and incorporation of the latter modification into DNA as an acceptable 
precursor within the nucleotide pool. 
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SECONDARY PROJECT (UNPUBLISHED) 
Materials and Methods 
Tumor Specimens 
The human brain tumor specimens were supplied in partnership with the laboratory 
of Dr. David Fortin. Any manipulations performed on these specimens conformed to the 
criteria accepted by the Comité d’éthique de la recherché en santé chez l’humain du Centre 
Hospitalier Universitaire de Sherbrooke (August 12, 2013). All information concerning the 
source of the tumors remained confidential and unknown to the experimenters; only the 
type and grade of the tumor was provided. The tumors were classified according to the 
WHO criteria. 
Sample Preparation 
One hundred and thirty brain tumors were obtained from surgery, which consisted of 
GBM (n=79) and early stage astrocytoma (n=51) specimens. Each tumor specimen was 
dissolved in DNA extraction buffer and homogenized after their arrival the same day of 
surgery. The subsequent DNA extraction, digestion and LC-MS/MS analysis (Figure 5) 
were performed following the same methods as previously outlined in Article 1 method 
section. However, the incubation period with protease during the DNA extraction was done 
for 4h rather than 2h. 
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Figure 5. LC-MS/MS analysis of 5-methylcytosine oxidation products in DNA. 
LC-MS/MS analysis of modified nucleosides showing the separation of 5hmC, 5hmU, 
5mC, 5fU and 5fC. Each product is superimposed with the corresponding 15N-labeled 
standard. The natural product is in blue, whereas the label standard is in red. 
 
Statistics 
A Spearman (rs) value from a linear fit of the data was calculated, along with the 
student t-test in origin. 
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Results 
Comparison of methyl cytosine related modifications in tumor specimens 
Quantification of 5mC and its related modifications using LC-MS/MS showed 
interesting results whilst comparing GBM (grade IV) specimens with low grade 
astrocytomas (grade II and III). Levels of 5mC within GBMs were on average 4.06 ± 
1.41%/cytosine and for low grade tumors the percentage was of 3.89 ± 0.95%/cytosine 
(Figure 6). Thus, there was no significant variation of 5mC between the two groups.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Levels of 5mC in brain tumors 
Percentages of 5mC in GBM (grade IV; in grey) tumors compared to low grade brain 
tumors (grade II+III; in blue). Error bars designate the standard deviation among collected 
values.   
 
In contrast, levels of 5hmC did vary between GBMs and low grade tumors. The 
percentages of 5hmC are shown in Figure 7, where they illustrate a variation in these levels 
from 0.16 ± 0.14 (grade II & III) to 0.095 ± 0.057 (grade IV). This variation displays a 
strong significant reduction of 1.75-fold (p = 5.18e-05) in 5hmC levels in GBM specimens. 
5fC levels, also displayed in Figure 7, showed a small decrease in its levels in GBM 
compared to grade II and grade III tumors. However, the decrease was not significant  (p = 
0.22).  
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Figure 7. Levels of 5hmC and 5fC in brain tumors 
Average levels of 5hmC (left) and 5fC (right) in GBM (grade IV; in grey) tumor 
DNA compared to low grade brain tumors (grade II+III; in blue). ** Indicates a significant 
(p<0.01) reduction in levels present in GBM compared to Grade II + III specimens. The 
error bars designates the standard deviation amongst collected values from the two tumor 
groups.   
 The deaminated derivatives of both 5hmC and 5fC were also quantified within these 
tumor specimens. Levels of 5hmU varied from 0.073 ± 0.073 in grade II and III tumors to 
0.052 ± 0.087 in GBM. This indicated a reduction in 5hmU levels to a significant statistical 
level (p = 0.018) (Figure 8). The distribution of related modifications also extended to 5fU. 
The percentage of 5fU within the tumor samples was significantly reduced from an average 
of 0.058%/cytosine (grade II & III) to 0.0075%/cytosine (p = 0.02) (Figure 8). Thus, the 
levels of several 5mC demethylation intermediates were greatly reduced with the 
development and growth of GBMs. 
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Figure 8. Levels of 5hmU and 5fU in brain tumors 
Average levels of 5hmU (left) and 5fU (right) in tumor DNA in GBM (grade IV; in 
grey) in comparison to low grade brain tumors (grade II+III; in blue). Significant reduction 
in levels present in GBM compared to Grade II + III specimens are illustrated by * 
(*p<0.05; **p<0.01). The error bars designate the standard deviation amongst collected 
values from independent tumor groups.  
Correlations between modifications 
 To further understand the unusual reduction in the 5mC base modifications, we 
investigated possible correlations between 5mC and its demethylation intermediates (Table 
1). Among the GBM specimens (grade IV; n=79), two strong correlations were observed. 
The first was between 5mC and 5hmC and the second was with 5mC and 5fC whose 
Spearman correlation (rs) value of 0.34 and 0.48, respectively (Figure 9A & 9B). On the 
other hand, in the grade II and grade III (n=51) tumors there was no correlation between 
these same modifications.  
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Table 1. Correlations of 5mC and demethylation intermediates 
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5fU 0.409 0.705 0.053 0.004 
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X X X X 
5hmC 0.459 
 
X X X 
5fC 0.445 0.07 
 
X X 
5hmU 0.278 0.041 0.002 
 
X 
5fU 0.784 0.168 0.029 0.001 
 
GBM (grade IV; n=79) and grade II, III gliomas and secondary GBM (n=51). Spearman rs 
value from a linear fit for the data: The correlation is significate at a bilateral level Blue 
(p<0.05), Red (p<0.01). 
 
Figure 9. Correlation between 5mC with 5hmC and 5fC 
Correlation between 5hmC and 5mC in GBM (n=76) (A). Along with the correlation of 5fC 
with 5mC in GBM (n=78) (B).  
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DISCUSSION 
 The level of 5hmC in the DNA of cancer cells is lower than that observed in normal 
cells as shown in numerous cases: myeloid malignancies, melanoma, and carcinomas of 
prostate, breast, colon, liver, lung and pancreas, using either immunohistochemistry or 
more quantitative mass spectrometry assays (Kudo et al. 2012; Gambichler et al. 2013; C. 
Liu et al. 2013; Yang et al. 2013). The primary project of this research was to study the 
effect of treating brain tumor cells with 5mC and related modifications in order to vary the 
levels of these modified nucleosides in genomic DNA.  The secondary project allowed a 
deeper understanding of brain tumors through the epigenetic correlations present amongst 
the modified bases within low grade tumors (grade II and grade III) and GBM specimens. 
Both projects looked towards the goal to have a better understanding of the possible 
mechanisms involved in the characteristic low levels of 5hmC within brain tumors.  
DNA Hypo/Hypermentylation 
Global hypohydroxymethylation, i.e. reduced level of 5hmC, is a phenomenon that 
has been synonymous with cancer development. Various studies have demonstrated the 
loss of 5hmC within brain cancer, and showed that these levels are further reduced during 
the progression of the cancer; with the lowest levels in GBMs (Cadieux 2006; Ehrlich 
2009; Hervouet et al. 2009). Globisch and colleagues have previously quantified the levels 
of 5mC within mouse brain tissue, and have found its levels ranged at about 4.30±0.22% 
/guanine, but they have also quantified 5hmC to be within a range of 0.3-0.7% /guanine 
(Globisch et al. 2010). Their results as well as ours are in agreement with previous studies 
(Vanyushin et al. 1998; Münzel et al. 2010).  Many previous studies performed using LC-
MS and antibody based approaches (Cadieux 2006; Ehrlich 2009; Hervouet et al. 2009), 
have mentioned the presence of global reduction of 5mC (hypomethylation) in cancerous 
tissue. In circumstances, hypomethylation may be attributed to oxidative stress mediated in 
particular by ROS. When ROS reacts with 5mC, the resulting product can change base 
pairing properties, thus DNA repair mechanisms are set in motion to excise 5mC and 
replace it with cytosine (Wu & Zhang 2010). Therefore the levels of 5mC would be 
reduced. However, our results did not indicate any variations amongst 5mC levels between 
GBMS and grade II/III brain tumors. Barciszewaka and co-workers measured 5mC in the 
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DNA of brain tumors by thin-layer chromatography (TLC) reporting the R value that was 
calculated from the ratio of 5mC/(5mC+C+T) multiplied by 100 to ascertain the 
percentages. They have demonstrated the variations of 5mC between astrocytoma (grade 
II), anaplastic astrocytoma (grade III) and GBM (grade IV), with R value results of 1.5, 1.0 
and 0.5 respectively (Barciszewska et al. 2014).  Therefore, they showed that the levels of 
5mC become reduced during tumor growth. However, unlike other studies, they did not 
compare the levels in tumors to the levels in normal brain tissue. Therefore, it would be 
difficult to assess if there was global hypomethylation.  Nonetheless, we did not observe 
the signature of global DNA hypomethylation in cancer in general, nor did we observe any 
variations in 5mC amongst the tumors grades. Our analysis is likely a better assessment of 
the level of methylation in brain tumors because it is based on LC-MS/MS, which is a more 
accurate and specific than TLC. 
 A possibility to explain the lack of hypomethylation (i.e., a decrease in 5mC) may 
involve hypermethylation (an increase in 5mC) that compensates for the decrease in 5mC 
and that can occur in different areas of the genome. Generally, hypomethylation has been 
reported in tumor DNA on a global scale, but it is far less common within regulatory 
regions (Ehrlich 2009; Hattori & Ushijima 2014). In these circumstances,  
hypermethylation, an increase in DNA methylation, also occurs during tumor formation, 
but is most predominant in CpG islands within gene promotor regions (Salem et al. 2000; 
Brock et al. 2003). This causes an inactivation of specific genes that promotes 
tumorigenesis (Bird 1986; Sidiropoulos et al. 2005). It can affect tumor suppressor genes 
such as O6-methylguanine-DNA-methyltransferase (MGMT) and numerous proteins 
involved in DNA repair, for example, the human Mut T homologue 1 (hMTH1) (Iida 2001; 
Hegi et al. 2009; Hattori & Ushijima 2014). Hypermethylation of MGMT promoter is an 
early event in tumorigenesis and the extent of methylation is considered as a bio-marker 
towards the response of GBM to alkylating chemotherapeutics, such as temozolomide 
(Hegi et al. 2009; Weller et al. 2010).  
However, gene promotor hypermethylation may be an unlikely cause for the absence 
of differences between grade II/III and GBM specimens. In these circumstances, there may 
be an alternative explanation. A recent publication from Thienpont and co-workers was 
shown how hypoxic environments within tumors leads to DNA hypermethylation. In these 
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instances, they have exposed human and murine cell line to both normal oxygen (O2) levels 
(21% O2) levels, termed normoxic, and also to a 0.5% O2 atmosphere, which would mimic 
a hypoxic environment. Using LC-MS methods, they demonstrated that genomic levels of 
5hmC were greatly reduced, due to a reduction in TET activity, which requires the presence 
of O2 in order to keep an adequate supply of alpha-ketoglutarate (α-KG) as a co-factor; in 
turn, this would lead to DNA hypermethylation due to reduced levels of 5mC being 
oxidized by TET  (Thienpont et al. 2016). Therefore, the natural hypoxic environment that 
comes with the development of a tumor can lead to a reduction in 5hmC an alternative 
characteristic in cancers as well. 
5hmC in brain tumors 
The 5hmC levels quantified within the tumor specimens confirm previous studies 
using LC-MS/MS methods (Jin, Jiang, et al. 2011; Kraus et al. 2012) and another using 
antibodies, which have reported low levels of 5hmC in brain cancer specimens (Orr et al. 
2012; Waha et al. 2012).  
5HmC levels may be abnormally low within brain tumors, and they are further 
reduced in the progression of cancer. In the cellular experiments that we performed, the 
levels of 5hmC were artificially increased through incubation of the cells with 5hmC 
(Article 1).  Thus, 5hmC in cell culture likely enters cells and undergoes phosphorylation to 
a monophosphorylated derivative. In its monophosphate form, the molecule can be a 
substrate for nucleoside kinases to perform subsequent phosphorylation of the molecule 
going from mono- to di- to finally the triphosphorylated derivative at which point it can 
become incorporated into genomic DNA. This process, similar to nulceotide salvage, was 
described previously for other DNA damage products including 5-hydroxycytosine and 5-
hydroxyuracil (Wagner et al. 1997). The triphosphate derivative of modified and 
nonmodified nucleosides with a similar structure are efficiently incorporated into genomic 
DNA by means of DNA polymerases during cell division (Prem veer Reddy & Pardee 
1980; Purmal et al. 1994; Wagner et al. 1997).  
However, various studies mention the reduced function of DNMTs, in particular 
DNMT1, which appears to be an early event in the development of many tumors (Cadieux 
2006). Gaudet and colleagues have performed experiments on mice with a hypomorphic 
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allele of DNMT1. They observed that the resulting hypomethylation within mice developed 
aggressive lymphomas (Gaudet et al. 2003). The lack of activity of DNMT1 did not only 
accelerated cancer formation, but it also led to an increase in mutation rates (Jaenisch et al. 
1998; Eden et al. 2003). However, a reduction in DNMT1 may not directly cause the 
formation of cancer. It enhances the parameters that would create the opportunity for its 
formation. The reduction in 5hmC levels noted in tumors may not always be an initial 
cause to the development of tumors (i.e glioblastoma). In example, the knock-out or down 
regulation of TET may lead to either inducing or accelerating cancer formation (Yang et al. 
2013; Thienpont et al. 2016).Except, it could also be a consequence of the events due to the 
reduction in the levels of 5mC required by TET, which would oxidized 5mC giving rise to 
5hmC; hence, indirectly reducing 5hmC levels within the cancer’s genome.  
We did not observe any reduction in 5mC levels within the tumor tissues, thus it 
cannot be a cause of the reduction in 5hmC levels. To fully rule out the implications of 
DNMT in the reduction of epigenetic levels, there may be an experiment that could be 
conducted. We have mentioned that there are three different types of DNMTs that are 
implicated in DNA methylation, however, the methods in which they methylate DNA 
remains the same. S-adenosylmethionine (SAM) is a methyl donor, which transfers its 
methyl group to DNMT for the methylation of cytosine in DNA. In doing so, SAM 
becomes transformed into S-adenosylhomocysteine (SAH), and DNMT adds the methyl 
group to cytosine making 5mC (Figure 10A) (Geisel et al. 2005). Hence, if we conduct a 
cell treatment of primary tumor cells following the same methods as those performed in 
article 1 there may be a means to examine DNMT’s function within the cancerous cells. In 
these circumstances, we would incubate the cells with methionine that is labeled with 
carbon C13 and deuterium (D), which would be added to the C5 position of cytosine in 
DNA. The resulting 5mC would be specifically labeled with the C13 (x1) and D (x3) giving 
a mass that is +4 higher than the natural 5mC (Figure 10B). Because the differences in 
mass may be discriminated by LC-MS/MS analysis, we would be able to examine the 
kinetics by which supplemented label methionine becomes incorporated into the DNA 
through DNMT activity.  
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Figure 10. DNA methylation with the aid of S-adenosylmethionine 
DNA methylation requires the donation of a methyl group from S-adenosylmethionine 
(SAM), which allows DNMT to transfer the methyl group to cytosine, and consequently 
SAM becomes transformed to S-adenosylhomocysteine (SAH) (figure A). (B) Same 
process is used for the DNA methylation, but the methyl group is replaced by a C13 and 
deuterium (CD3) compounds, which labels the methyl group in 5mC giving 5mC-L.   
 
Implications of TET 
The correlation that we have observed between 5mC with 5hmC and 5fC in GBMs 
and yet, absent in the grade II and grade III tumors, supports the involvement of TET 
enzymatic activity within cancerous tissue. TET activity within the high grade tumors, 
GBMs, indicates that there is no indication of an impairment of the enzymatic activity since 
the conversion of 5mC to 5hmC and 5fC is strongly correlated (Figure 11). Thus far, 
various studies do not support changes in TET activity in GBM as a cause to explain the 
low global levels of 5hmC in the tumor genome (Kraus, Greiner, et al. 2015).  
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Figure 11. Demethylation pathway promoted in GBMs  
Within GBMs sample there was a strong correlation between 5mC, 5hmC and 5fC, which 
suggests that the demethylation pathway mediated by TET is still functional and promoted 
in GBM (n=76) compared to stage II/III and secondary GBM.  
 
However, the absence of a correlation within the low grade astrocytomas indicate 
the impairment of TET, which would be caused by mutations in IDH1 mutations. IDH1 and 
IDH2 proteins perform a catalytic reaction, which converts isocitrate to α-ketogluatrate (α-
KG), which is a cofactor required by TET enzymes to oxidize 5mC in DNA (Kriaucionis & 
Heintz 2009; Münzel et al. 2010; Lu et al. 2015). IDH mutations have been detected within 
various cancers (McKenney & Levine 2013; Scourzic et al. 2015). Such mutations change 
the product of enzyme activity from the formation of α-KG to the formation of a α-
hydroxygluatrate, which is an inhibitor of TET enzymatic activity; thus, inhibition of TET 
activity leads to a reduction of 5hmC in certain types of tumors (Jin, Jiang, et al. 2011). In 
brain tumors, IDH1 mutations have only been observed in grade II and grade III tumors 
(Jin, Jiang, et al. 2011), where 70% of grade II and grade III astrocytomas had mutations 
pertaining to IDH1 (Jiao et al. 2012; Kannan et al. 2012; Liu et al. 2012; Suvà 2014). Our 
findings strongly support the presence of IDH mutations in grade II-III tumors. The strong 
correlation between 5mC modification (5hmC and 5fC) within GBM, that are absent in 
grade II-III tumors suggest that IDH1 mutations are implicated in the latter. However, the 
levels of 5hmC and other modifications are lower in the GBMs in comparison with low 
grade tumors, suggesting that there are alternative pathways to explain the loss of 5hmC in 
these tumors specimens.  
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Deamination activity 
A novelty in this project was the quantification of 5fC, 5hmU and 5fU within the 
DNA of low grade tumors and GBMs. These modifications were detected previously, in 
mouse embryonic stem cells, where their levels were about a hundred times lower than 
5hmC (Pfaffeneder et al. 2011). However, these modifications have not been previously 
measured within brain tissues. There was very little difference in the levels of 5fC between 
low grade tumors and GBMs. However, the values of 5hmU observed in brain tumors 
appear to be much lower than those reported in normal brain tissue from animals. 
Liu and associates (S. Liu et al. 2013) used LC-MS/MS/MS methods in order to 
quantify the levels of 5hmC, 5fC, 5caC and 5hmU by calculating the ratio of moles of 
modified nucleoside with respect to all nucleosides. They measured the levels of these 
compounds within HEK293T cells, mouse embryonic stem cells, and HELA cells, but as 
well as in mouse and human brain tissue. They demonstrated the variations of these 
compounds within different cell lines and tissues. In particular, the level of 5hmU was 3.9 
moles per 106 nucleosides within human brain tissue, whereas in cancerous tissue, the 
levels were reduced to 3.0 per 106 nucleosides giving a difference of 1.3-fold (S. Liu et al. 
2013). Whilst comparing their results with ours, it is evident that our results are 
dramatically higher than the levels they have reported. It is important to note that the 
human tissue that Liu and co-workers used was from healthy human cerebellums, whilst we 
were observing these levels within brain tumors that arises predominantly within the cortex. 
Globisch and associates have mentioned variations in 5hmC levels within the various 
locations of the brain. For example, they found that the pituitary gland located in the brain 
have levels of only 0.06%/guanine, thus it is why they give a range for 5hmC levels (0.3-
0.7%) (Globisch et al. 2010). Therefore, if there are variations in 5hmC levels within the 
brain location, it may be possible that the same could be said for 5hmU. 
Another possibility is that a certain amount of 5hmU was fabricated through 
artificial oxidation of thymine during sample preparation involving tissue homogenization, 
DNA extraction and digestion. In the article of Wang and co-workers (Wang et al. 2011), 
the reported levels of 5hmU was 0.088%/cytosine in mouse brain, which is 3-4 fold higher 
than the values reported in brain tumors in the present study. Further studies will be 
necessary to evaluate the contribution of 5hmU in our samples and rule out artificial 
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oxidation as a cause of the higher levels of 5hmU in brain tumors compared to healthy 
brain tissue. 
The presence of 5hmU and 5fU in the DNA of brain tumors points to the 
deamination of 5hmC to 5hmU and likewise for the deamination of 5fC to 5fU. The 
relatively high level of 5hmU in brain tumors can be explained by two pathways: 1) 
deamination of 5hmC directly in DNA by AID/APOBEC or 2) recycling of DNA 
containing 5hmC through the nucleotide pool together with CDA activity to convert 5hmC 
nucleotides to 5hmU nucleotides that subsequently are incorporated into cellular DNA 
(Figure 12). Deamination of 5hmC in DNA (pathway 1) can be mediated by the family of 
AID/APOBEC that have been well studied in the deamination of cytosine to uracil (Nabel, 
Manning, et al. 2012). Furthermore, this enzyme has been suggested to play a critical role 
in the deamination of 5hmC within the mammalian brain (Guo et al. 2011). Supporting the 
first explanation (deamination by AID/APOBEC), we observed significant correlations 
between 5hmC, 5fC, 5hmU and 5fU in the DNA of grade II and III tumors (Table 1). 
However, here is still much debate behind the importance of deamination activity of 
AID/APOBEC enzymes on modified cytosine. Although, Guo and associates (Guo et al. 
2011) showed that it accounted for 5hmU within mouse brain DNA, Nabel and co-workers 
(Nabel, Jia, et al. 2012) showed that 5mC and 5hmC opposite G are poor substrates for 
purified AID-APOBEC. Thus, AID/APOBEC likely only accounts for small amounts of 
5hmU within the genomic DNA of the brain.  
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Figure 12. Epigenetic salvage and reincorporation process 
A plausible pathway that may explain the high levels of 5hmU and 5fU. Illustrated above, 
is the case of 5hmC, where it would be excised form DNA and stored in the nucleotide pool 
part of a salvage/recycling process. CDA would then deaminate 5hmC prior to it be 
phosphorylated and reincorporated into genomic DNA.  
 
On the other hand, our studies support the second possibility (pathway 2: recycling 
or salvage of 5hmC). In article 1, we show that cells take up 5hmC in cell culture and 
subsequently remove the amino group by CDA activity and then incorporate the 
deaminated nucleotide into DNA. The recycling process of 5hmC into 5hmU also occurs 
for 5fC. The greater amount of 5hmU and 5fU in grade II and III tumors compared to GBM 
may be explained by either greater turnover of cells or greater CDA activity in the less 
severe grade tumors. With the addition of dTHU to the experiment, one can estimate that 
CDA activity accounted for approximately 50% of the amount of 5hmU that persisted in 
cellular DNA. This suggests that cells possess alternative CDA-like activity that is not 
inhibited by THU to preclude the incorporation of 5hmC into cellular DNA during salvage. 
In conclusion, we propose that the unusually high levels of 5hmU in the DNA of tumor 
specimens is explained by a recycling/salvage process, followed by deamination by CDA, 
phosphorylation by kinases, and then incorporation of 5hmU into DNA by DNA 
polymerase during cell division. 
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CONCLUSION 
The most dramatic changes of 5hmC levels are observed in brain cancer. Several 
pathways have been proposed to explain the demethylation of 5mC, although much remains 
unclear and few studies have addressed brain tumors. A likely pathway seems to be the 
impairment of the TET enzymes by possible IDH1 mutations. However, this work also 
suggests that there may be alternative pathways that emphasize the deamination activity to 
5hmU and 5fU. 
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